Longitudinal Analysis of Respiratory Function of Different Types of Limb Girdle Muscular Dystrophies Reveals Independent Trajectories

The prevalence and progression of respiratory muscle dysfunction in patients with limb girdle muscular dystrophies (LGMDs) has been only partially described to date. Most reports include cross-sectional data on a limited number of patients making it difficult to gain a wider perspective on respirato...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurology. Genetics 2023-08, Vol.9 (4), p.e200084-e200084
Hauptverfasser: Muni-Lofra, Robert, Juanola-Mayos, Eduard, Schiava, Marianela, Moat, Dionne, Elseed, Maha, Michel-Sodhi, Jassi, Harris, Elizabeth, McCallum, Michelle, Moore, Ursula, Richardson, Mark, Trainor, Christina, Wong, Karen, Malinova, Monika, Bolano-Diaz, Carla, Keogh, Michael John, Ghimenton, Elisabetta, Verdu-Diaz, Jose, Mayhew, Anna, Guglieri, Michela, Straub, Volker, James, Meredith K, Marini-Bettolo, Chiara, Diaz-Manera, Jordi
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The prevalence and progression of respiratory muscle dysfunction in patients with limb girdle muscular dystrophies (LGMDs) has been only partially described to date. Most reports include cross-sectional data on a limited number of patients making it difficult to gain a wider perspective on respiratory involvement throughout the course of the disease and to compare the most prevalent LGMD subtypes. We reviewed the results of spirometry studies collected longitudinally in our cohort of patients in routine clinical visits from 2002 to 2020 along with additional clinical and genetic data. A linear mixed model was used to investigate the factors associated with the progression of respiratory dysfunction. We followed up 156 patients with 5 different forms of LGMDs for a median of 8 years (range 1-25 years). Of them, 53 patients had pathogenic variants in the gene, 47 patients in the gene, 24 patients in the gene, 19 in the gene, and 13 in one of the sarcoglycan genes (SCG). At baseline, 58 patients (37.1%) had a forced vital capacity percentage predicted (FVCpp) below 80%, while 14 patients (8.9%) had peak cough flow (PCF) values below 270 L/min. As a subgroup, was the group with a higher number of patients having FVC
ISSN:2376-7839
2376-7839
DOI:10.1212/NXG.0000000000200084